LEXINGTON, MA, USA I July 07, 2025 I Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab ...

The growing prevalence of chronic diseases is a major factor driving revenue growth in the natural killer (NK) cell ...

CSL Behring Germany today announced that the first haemophilia B patient in Germany was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Hemophilia Treatment Center at ...